These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9305443)

  • 1. HIV-1 viral dynamics and viral load measurement: implications for therapy.
    Riddler SA; Mellors JW
    AIDS Clin Rev; 1997-1998; ():47-65. PubMed ID: 9305443
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV therapeutics: points from the recent literature.
    Laurence J
    AIDS Read; 2003 Jul; 13(7):305, 307. PubMed ID: 12889448
    [No Abstract]   [Full Text] [Related]  

  • 3. Virologic testing in the management of perinatal HIV exposure.
    Cervia J; Kaplan B; Schuval S; Weiss S
    AIDS Read; 2003 Jan; 13(1):39-47. PubMed ID: 12569894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral therapy in human immunodeficiency virus-infected individuals.
    Spooner KM
    Adv Intern Med; 1998; 43():373-402. PubMed ID: 9506188
    [No Abstract]   [Full Text] [Related]  

  • 5. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].
    Marcello A; Giacca M
    Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891
    [No Abstract]   [Full Text] [Related]  

  • 6. Advances in the virology of HIV infections and implications for clinical management.
    Vella S
    AIDS Clin Care; 1998 Mar; 10(3):17-9. PubMed ID: 11365117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.
    Masquelier B; Pereira E; Peytavin G; Descamps D; Reynes J; Verdon R; Fleury H; Garraffo R; Chêne G; Raffi F; Brun-Vézinet F;
    J Clin Virol; 2005 May; 33(1):75-8. PubMed ID: 15797369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection.
    Fialaire P; Payan C; Vitour D; Chennebault JM; Loison J; Pichard E; Lunel F
    J Infect Dis; 1999 Aug; 180(2):574-5. PubMed ID: 10395889
    [No Abstract]   [Full Text] [Related]  

  • 9. Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy.
    Galli M; Balotta C; Meroni L; Colombo MC; Papagno L; Bagnarelli P; Testa L; Varchetta S; Colombo L; Moroni M; d'Arminio Monforte A; Clerici M; Clementi M
    AIDS; 1998 Dec; 12(18):2500-2. PubMed ID: 9875591
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia.
    Podsadecki TJ; Vrijens BC; Tousset EP; Rode RA; Hanna GJ
    J Infect Dis; 2007 Dec; 196(12):1773-8. PubMed ID: 18190257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of an intermittent episode of viremia.
    Di Mascio M; Percus JK; Percus OE; Markowitz M; Ho DD; Perelson AS
    Bull Math Biol; 2005 Jul; 67(4):885-900. PubMed ID: 15893558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma viral load testing in the management of HIV infection.
    Mylonakis E; Paliou M; Rich JD
    Am Fam Physician; 2001 Feb; 63(3):483-90, 495-6. PubMed ID: 11272298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients.
    Van Laethem K; De Luca A; Antinori A; Cingolani A; Perna CF; Vandamme AM
    Antivir Ther; 2002 Jun; 7(2):123-9. PubMed ID: 12212924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral kinetics: implications for treatment.
    Young B; Kuritzkes DR
    AIDS; 1999 Sep; 13 Suppl 1():S11-7. PubMed ID: 10546781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 DNA and RNA kinetics in primary HIV infection.
    Lillo F; Grasso M; Lodini S; Capiluppi B; Lazzarin A; Tambussi G
    J Biol Regul Homeost Agents; 2002; 16(1):49-52. PubMed ID: 12003174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 viral load and clinical outcome: review of recent studies.
    Riddler SA; Mellors JW
    AIDS; 1997; 11 Suppl A():S141-8. PubMed ID: 9451978
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative potency of three antiretroviral therapy regimes in primary HIV infection.
    Fidler S; Fraser C; Fox J; Tamm N; Griffin JT; Weber J
    AIDS; 2006 Jan; 20(2):247-52. PubMed ID: 16511418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 drug resistance assays in clinical management.
    Martinez-Picado J; D'Aquila R
    AIDS Clin Care; 1998 Nov; 10(11):81-5, 87-8. PubMed ID: 11365861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New biological monitoring of HIV infection].
    Morand-Joubert L
    Rev Prat; 1998 Mar; 48(5):472-7. PubMed ID: 9781107
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.